Pharmacokinetics and bioavailability of nutraceuticals

Mittal, Swati; Sawarkar, Sujata; Doshi, Gaurav; Pimple, Prachi; Shah, Jenny; Bana, Turabali

doi:10.1016/b978-0-12-824312-1.00021-2

Cited by 4 publications

(1 citation statement)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, the results revealed that Storg B has potential humoral immunity and can be a potential therapeutic candidate for several immunesuppressed conditions. Any molecule's bioavailability (BA) is determined by the interaction of its pharmacodynamics (PDs) and pharmacokinetics (PKs) factors [32]. PKs (ADME) and PDs are two aspects that influence the therapeutic efficacy of drugs.…”

Section: Discussionmentioning

confidence: 99%

In vitro Antioxidant, In vivo Bioavailability, and Immunomodulatory Effects of a Polyherbal Formulation (Storg B) Induced by Cyclophosphamide in an Experimental Animal Model

Firoz H M,

Sadashiva C T,

Sahana C V

2024

J. Pharm. Res. Int.

View full text Add to dashboard Cite

Introduction: The immunomodulatory properties of plants are being extensively explored these days as they contain a wide range of bioactive compounds that can treat immunomodulatory disorders. The aim of the present investigation was to determine the efficacy of the standardized polyherbal formulation (Storg-B). The Storg-B combines Psidium guajava, Mangifera indica, and Citrus limon. Methods: The aqueous extract of the Storg B was investigated for DPPH radical scavenging activity to determine antioxidant activity. SD rats were selected for the evaluation of the immunomodulatory activity of Storg-B. The haemagglutination and hematology methods were used to evaluate the immunomodulatory studies. For the pharmacokinetic studies, the LC-MS/MS technique is employed to quantify Storg B. Results: The percentage inhibition of DPPH radial IC50 values of standard BHT and Storg-B were 60.52 and 68.35µg/ml, respectively. In the in vivo animal studies, Storg-B showed significant immunomodulatory activity by increasing the primary and secondary antibody titer values by 6.58 and 8.25 mg/mL, respectively, for the SRBC antigen at a dose of 100 mg/kg. There’s also an increase in the neutrophil adhesion percentage at the testing doses. Results of hematological parameters revealed that Storg-B restored all the levels of blood components at a 100 mg/kg dose. A Storg-B showed greater potency in the bioavailability studies. Conclusion: Thus, the Storg-B used as an efficient and secure formulation in the treatment of immune deficiency by improving the immune response.

show abstract

Section: Discussionmentioning

confidence: 99%